The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy
Fig 1
Combined treatments of CBP-93872 with oxaliplatin, cisplatin, 5-FU, or gemcitabine effectively suppresses cell growth.
(A) HT29 cells were treated with the indicated concentrations of CBP-93872 for 72 hrs, followed by WST-1 assay. Data are presented as means ± SD (n = 3). (B) Panc-1 cells were treated with the indicated concentrations of CBP-93872 for 72 hrs, followed by WST-1 assay. Data are presented as means ± SD (n = 3). (C) HT29 cells were treated with CBP-93872 (50 μM) in combination with indicated concentrations of oxaliplatin, cisplatin or 5-FU for 72 hrs, followed by WST-1 assay. (D) Panc-1 cells were treated with CBP-93872 (200 μM) in combination with indicated concentrations of oxaliplatin, cisplatin or gemcitabine for 72 hrs, followed by WST-1 assay. The black bars show individual treatments; while the white bars show combined treatment with CBP-93872. Data are presented as means ± SD (n = 3). Statistical significance was calculated using Student’s t-test (*, p < 0.01) (C, D).